Yutaka Shimizu

No ORCID on file · 14 papers in corpus · active 2007-2022

Study types

  • article 10
  • other 2
  • review 2

Condition tags

  • endometriosis 8
  • dysmenorrhea 1
  • adenomyosis 1
review 2022
Advances in therapy ·doi:10.1007/s12325-022-02298-9

INTRODUCTION: Although several studies suggest beneficial effects of low-dose estrogen-progestins (LEPs) and progestins on dysmenorrhea in Japanese women, the difference in efficacy between drugs remains unknown. METHODS: We identified stud…

other 2017
European journal of obstetrics, gynecology, and reproductive biology ·doi:10.1016/j.ejogrb.2017.04.048

OBJECTIVE: C-C motif chemokine ligand 20 is thought to contribute to the development of endometriosis by recruiting Th17 lymphocytes into endometriotic foci. The present study investigated the effects of dienogest, a progesterone receptor a…

article 2014
The Journal of steroid biochemistry and molecular biology ·doi:10.1016/j.jsbmb.2014.12.008

Dienogest (DNG) is a selective progesterone receptor (PR) agonist and oral administration of DNG is used for the treatment of endometriosis. DNG is considered to act on PR to down-regulate pathophysiological factors associated with endometr…

article 2014
European journal of obstetrics, gynecology, and reproductive biology ·doi:10.1016/j.ejogrb.2014.03.019

ObjectiveTo determine the immunological effect of dienogest (DNG), an oral anti-endometriosis drug, on peritoneal fluid (PF) macrophages collected from women with endometriosis. Although it has been suggested that DNG has direct effects on …

other 2014
European journal of obstetrics, gynecology, and reproductive biology ·doi:10.1016/j.ejogrb.2014.05.031

OBJECTIVES: To investigate the direct effects of progesterone receptor (PR) agonists on proliferation and apoptosis of human adenomyotic cells. STUDY DESIGN: Human primary cultures of adenomyotic stromal cells (ASCs) from 24 patients with …

article 2013
Fertility and sterility ·doi:10.1016/j.fertnstert.2013.10.038

ObjectiveDienogest (DNG), a selective P receptor (PR) agonist, is used to treat endometriosis. To investigate whether DNG affects nerve growth factor (NGF) expression, we stimulated human endometrial epithelial cells (hEECs) with inflammato…

article 2012
Fertility and sterility ·doi:10.1016/j.fertnstert.2011.11.005

ObjectiveTo determine the effect of dienogest (DNG) on the expression of aromatase and cyclooxygenase-2 (COX-2) and the production of prostaglandin E(2) (PGE(2)) in human endometriotic stromal cells (ESCs).DesignExperimental study in vitro.…

article 2011
·doi:10.1016/j.fertnstert.2011.09.040
article 2010
Steroids ·doi:10.1016/j.steroids.2010.08.010

Prostaglandin E(2) (PGE(2)) is a major mediator in the pathophysiology, and pathogenesis of gynecological diseases associated with abnormal endometrial disease with proliferation and inflammation, such as endometriosis. In this study, we in…

article 2010
Human Reproduction ·doi:10.1093/humrep/deq241

BACKGROUND: We aimed to establish an endometrial autograft model in rats that would allow for repetitive in vivo analyses of angiogenesis. Dienogest (DNG) is an orally active progestin used for the treatment of endometriosis. We investigate…

article 2009
Molecular human reproduction ·doi:10.1093/molehr/gap042

Dienogest is a specific progesterone receptor agonist with potent oral endometrial activity and is used in the treatment of endometriosis. In this study, we examined the direct effects of dienogest on the proliferation of human endometrial …

review 2009
Nihon yakurigaku zasshi. Folia pharmacologica Japonica ·doi:10.1254/fpj.133.32

ジエノゲスト(販売名:ディナゲスト錠1 mg)は,プロゲステロン受容体に対して選択的なアゴニスト活性を示す第4世代のプロゲスチンである.ジエノゲストは,ラットおよびウサギに経口投与することによりプロゲステロン作用を示し,一方,アンドロゲン作用,グルココルチコイド作用およびミネラルコルチコイド作用は示さなかった.ジエノゲストは,カニクイザルに反復経口投与することにより月経周期の停止,月経周期に伴う血中エストラジオール濃度の上昇および黄体形成ホルモン濃度の上昇を抑制し,卵巣機能抑…

article 2008
·doi:10.1007/bf03345616
article 2007
·doi:10.1016/j.steroids.2007.10.003